Please Wait
Applying Filters...
menu
    • menu
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    An Enquiry

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    An Enquiry

    Menu

    Tabelecleucel

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Pierre Announces Type A Meeting Agreed with Tabelecleucel BLA
    Pierre Announces Type A Meeting Agreed with Tabelecleucel BLA

    12 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/pierre-fabre-pharmaceuticals-announces-type-a-meeting-agreed-with-us-food-and-drug-administration-fda-for-tabelecleucel-biologic-license-application-bla-302711648.html

    PR NEWSWIRE
    12 Mar 2026
    Share Share
    Pierre Fabre Seeks FDA Type A Meeting For BLA of Tabelecleucel
    Pierre Fabre Seeks FDA Type A Meeting For BLA of Tabelecleucel

    03 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/pierre-fabre-pharmaceuticals-submits-type-a-meeting-request-to-us-food-and-drug-administration-fda-for-tabelecleucel-biologic-license-application-bla-302702368.html

    PR NEWSWIRE
    03 Mar 2026
    Share Share
    Atara Biotherapeutics Provides Regulatory Update On Tabelecleucel
    Atara Biotherapeutics Provides Regulatory Update On Tabelecleucel

    03 Mar 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260303134105/en/Atara-Biotherapeutics-Provides-Regulatory-Update-on-Tabelecleucel

    BUSINESSWIRE
    03 Mar 2026
    Share Share
    FDA Rejects Atara’s blood Cancer Treatment
    FDA Rejects Atara’s blood Cancer Treatment

    13 Jan 2026

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-declines-approve-ataras-therapy-rare-blood-cancer-2026-01-12/#:~:text=Jan%2012%20(Reuters)%20%2D%20The,down%2056%25%20in%20early%20trading.

    REUTERS
    13 Jan 2026
    Share Share
    Pierre Fabre Pharma Responds to Fda's CRL for Tabelecleucel
    Pierre Fabre Pharma Responds to Fda's CRL for Tabelecleucel

    12 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/pierre-fabre-pharmaceuticals-statement-regarding-receipt-of-complete-response-letter-for-tabelecleucel-biologics-license-application-from-the-us-food-and-drug-administration-302658114.html

    PR NEWSWIRE
    12 Jan 2026
    Share Share
    Pierre Fabre Announces Phase 3 Tabelecleucel Data in EBV+ PTLD
    Pierre Fabre Announces Phase 3 Tabelecleucel Data in EBV+ PTLD

    08 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/pierre-fabre-pharmaceuticals-announces-updated-phase-3-tabelecleucel-data-at-american-society-of-hematology-meeting-in-epstein-barr-virus-positive-post-transplant-lymphoproliferative-disease-ebv-ptld-302634289.html

    PR NEWSWIRE
    08 Dec 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.